Olajide Odunayo Sobande

Dr. Olajide Odunayo Sobande

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 July 2025 in PLOS Digital Health
Verified
Journal Article
Open access
PDF file
AEAdaeze E. Egwudo
Adaeze E. Egwudo
Ayodapo JegedeAyodapo Jegede
Ayodapo Jegede
TOTolulope A. Oyeniyi
Tolulope A. Oyeniyi
NENkolika Jacinta Ezekwelu
Nkolika Jacinta Ezekwelu
SASamirah N. Abdu-Aguye
Samirah N. Abdu-Aguye
OSOlajide Odunayo Sobande
Olajide Odunayo Sobande
Integrating digital health technologies (DHTs) in Nigeria’s healthcare system holds promise, yet the opportunities, challenges, and strategies influencing their success remain insufficiently explored. This scoping review aimed to map these factors, focusing on healthcare settings in Nigeria. A comprehensive search of databases (PubMed, Scopus, Web of Science, and CINAHL) and Google Scholar identified publications on DHT use in Nigeria from July 1, 2014, to June 30, 2024. A total of 31 observational and experimental studies were included involving healthcare workers, patients, caregivers, or other stakeholders impacted by DHT integration. Key findings revealed that DHTs enhanced treatment adherence, healthcare utilization, and community engagement while expanding technology infrastructure for scaling interventions. Notable opportunities included support and training and improved data quality. However, challenges such as operational and logistical barriers, inadequate network coverage, and cultural and gender sensitivity issues were prevalent. Strategies to address these challenges focused on continuous training for healthcare workers, community involvement to foster engagement, and data reporting and quality improvements. Despite their potential to transform healthcare delivery, particularly in underserved areas, successful integration of DHTs in Nigeria requires addressing infrastructure gaps, cultural norms, and operational challenges. Community engagement, capacity building for healthcare workers, and data-driven decision-making are critical to maximizing the impact of digital health interventions in Nigeria.

22 October 2025 in Journal of Medical Internet Research
Verified
Journal Article
Open access
Obinna Ositadimma OleribeObinna Ositadimma Oleribe
Obinna Ositadimma Oleribe
Andrew W. Taylor-RobinsonAndrew W. Taylor-Robinson
Andrew W. Taylor-Robinson
VAVetty R Agala
Vetty R Agala
OSOlajide Odunayo Sobande
Olajide Odunayo Sobande
Ricardo IzurietaRicardo Izurieta
Ricardo Izurieta
STSimon David Taylor-Robinson
Simon David Taylor-Robinson
Background: Artificial intelligence (AI) is increasingly being integrated into health care, offering a wide array of benefits. Current AI applications encompass patients’ diagnosis, treatment, data mining, and more to enhance patient care and quality of life. It is also democratizing access to expert support by providing timely and accurate disease diagnoses, better clinical management, quicker drug discovery, improved disease prevention, big data management, and health protection. Objective: The aim of the study is to document AI adoption in health care, assess participants’ perception on its usefulness in the management of health care delivery and leadership of health care systems, and identify characteristics of early adopters. Methods: We conducted a worldwide cross-sectional survey across all 6 inhabited continents using a self-administered questionnaire developed with the Qualtrics electronic data collection tool. This was piloted and reviewed to ensure completeness, accuracy, acceptability, cultural sensitivity, and relevance. Respondents were recruited by individualized email, following identification from professional associations or organizations, professional networks, and social media. Data were analyzed using SPSS (IBM Corp), with results presented as narrative, charts, and tables. Results: In total, 506 health care professionals completed the survey. While 92.3% (467/506) of respondents believed that AI has a role in patient care and health care management, only 76.5% (300/392) were willing to support AI adoption and embedding in their organization. Although top managers are mainly responsible for adoption processes, staff training remains low. AI is currently used mostly for diagnosis, patient care, and precision medicine. These uses of AI will continue in the near future, but in different ways. AI adoption was highest in Europe and lowest in Africa. Black or African American people were more likely to support AI adoption than White and Asian people. Poor knowledge of AI, fear of job loss, and resistance to change were the top barriers to AI adoption and embedding. Conclusions: AI use in health is global, but the adoption rate varies by geography and individual characteristics. AI adoption communication by executive health care management is poor, as is the level of training of health care staff. To improve AI adoption, management should improve communication with their teams, provide training on AI to their workers, and help individuals understand how AI works. Barriers such as ethical issues around data ownership and use should be addressed. African organizations should be proactive and invest in AI adoption early, so that they are not left behind in the AI revolution.

AOAzuka Patrick Okwuraiwe
Azuka Patrick Okwuraiwe
COChizaram A. Onyeaghala
Chizaram A. Onyeaghala
OOObiageli Theresa Ozoude
Obiageli Theresa Ozoude
MSMuritala Suleiman
Muritala Suleiman
SASamirah Abdu-Aguye
Samirah Abdu-Aguye
OSOlajide Odunayo Sobande
Olajide Odunayo Sobande
Lassa fever (LF) is an acute viral hemorrhagic fever that poses a substantial public health security threat in West Africa. The non-specific clinical presentation of LF, coupled with a lack of reliable point-of-care diagnostics, means delayed diagnosis, leading to severe complications and mortality during epidemics. A systematic review and meta-analyses were performed by conducting an extensive online search using PubMed, Web of Science, Scopus, CINAHL, and Google Scholar (PROSPERO protocol identifier number CRD42024587426). Only peer-reviewed studies written in English were included in publications from 1 September 2014, to 31 August 2024. The analysis and reporting followed PRISMA guidelines. The quality of the included studies was assessed using the critical appraisal tools developed from the Joanna Briggs Institute Systematic Review Checklist for cohort studies. We included 19 studies that contained data from 4177 patients hospitalized with LF of any age. Most included studies employed a retrospective cohort design and were conducted in Nigeria (16/19; 84.2%). The mortality rate was highest in a Sierra Leonean study (63.0%), whereas a group-based analysis of Nigerian studies using a random-effects model identified Owo as having the highest mortality rate of 13% (95% CI: 6–23; I2 = 98%). The pooled mortality rate for severe LF was 19% (95% confidence interval [CI]:10–32). The most common complications of LF are acute kidney injury (AKI) at a pooled proportion of 19% (95% CI; 13–26; I2 = 89%)), followed by abnormal bleeding at a pooled proportion of 17% (95% CI; 9–30; I2 = 98%), and central nervous system (CNS) dysfunction at a pooled proportion of 15% (95% CI; 6–32; I2 = 98%). With one out of every five hospitalized LF patients likely to die in West Africa, accelerating the development of rapid diagnostic tests, licensed vaccines, and novel therapeutics is crucial. Strengthening community engagement and risk communication, developing regional treatment guidelines, decentralizing LF care units, and training healthcare workers using a harmonized curriculum will enhance early diagnosis and effective case management, thereby reducing severe complications and mortality.

4 December 2025 in PLOS ONE
Verified
Journal Article
Open access
VAVictor Ayodeji Ayeni
Victor Ayodeji Ayeni
AAAisha Adam Abdullahi
Aisha Adam Abdullahi
AIAbdulmuminu Isah
Abdulmuminu Isah
LALove Bukola Ayamolowo
Love Bukola Ayamolowo
TATimothy Adeyemi
Timothy Adeyemi
OSOlajide Odunayo Sobande
Olajide Odunayo Sobande
Background: Perinatal asphyxia (PA) is a major contributor to neonatal mortality and long-term neurodevelopmental impairment, particularly in low- and middle-income countries (LMICs), where the effectiveness of therapeutic hypothermia remains limited. Pharmacologic neuroprotective agents have shown potential as alternative treatments, but their efficacy in low-income and lower-middle-income countries (LILMICs) is not well established. This systematic review aimed to assess the effectiveness of pharmacologic interventions in neonates with PA in LILMICs. Methods: A systematic search of PubMed, Web of Science, CINAHL, and Google Scholar was conducted for randomised controlled trials (RCTs) published between 2000 and 2024. Eligible studies compared pharmacologic neuroprotective agents with placebo or standard care, excluding therapeutic hypothermia, among neonates diagnosed with PA in LILMICs. Data on survival and neurodevelopmental outcomes were extracted and synthesized; meta-analyses were conducted where appropriate. Results: Twelve RCTs involving 1,008 neonates were included. The majority (91.7%) of studies were conducted in Asia, with only one study from Africa. Magnesium sulphate was the most frequently evaluated agent (66.7% of studies), followed by melatonin, topiramate, erythropoietin, and citicoline. Melatonin was associated with improved survival, and all agents showed improved short-term neurological outcomes. Neurodevelopmental outcomes at 3, 6, 12, and 19 months were generally favourable, though data remained limited. Conclusion: Pharmacologic neuroprotective agents show promise in improving survival and neurological outcomes in neonates with PA in LILMICs. However, more robust, multi-center RCTs are needed to confirm their efficacy and establish them as feasible alternatives to therapeutic hypothermia in these settings.

2 January 2025 in JMIR Preprints
Verified
Preprint
Open access
Obinna Ositadimma OleribeObinna Ositadimma Oleribe
Obinna Ositadimma Oleribe
Andrew W. Taylor-RobinsonAndrew W. Taylor-Robinson
Andrew W. Taylor-Robinson
VAVetty R Agala
Vetty R Agala
OSOlajide Odunayo Sobande
Olajide Odunayo Sobande
Ricardo IzurietaRicardo Izurieta
Ricardo Izurieta
STSimon David Taylor-Robinson
Simon David Taylor-Robinson
BACKGROUND Artificial intelligence (AI) is increasingly being integrated into health care, offering a wide array of benefits. Current AI applications encompass patients’ diagnosis, treatment, data mining, and more to enhance patient care and quality of life. It is also democratizing access to expert support by providing timely and accurate disease diagnoses, better clinical management, quicker drug discovery, improved disease prevention, big data management, and health protection. OBJECTIVE The aim of the study is to document AI adoption in health care, assess participants’ perception on its usefulness in the management of health care delivery and leadership of health care systems, and identify characteristics of early adopters. METHODS We conducted a worldwide cross-sectional survey across all 6 inhabited continents using a self-administered questionnaire developed with the Qualtrics electronic data collection tool. This was piloted and reviewed to ensure completeness, accuracy, acceptability, cultural sensitivity, and relevance. Respondents were recruited by individualized email, following identification from professional associations or organizations, professional networks, and social media. Data were analyzed using SPSS (IBM Corp), with results presented as narrative, charts, and tables. RESULTS In total, 506 health care professionals completed the survey. While 92.3% (467/506) of respondents believed that AI has a role in patient care and health care management, only 76.5% (300/392) were willing to support AI adoption and embedding in their organization. Although top managers are mainly responsible for adoption processes, staff training remains low. AI is currently used mostly for diagnosis, patient care, and precision medicine. These uses of AI will continue in the near future, but in different ways. AI adoption was highest in Europe and lowest in Africa. Black or African American people were more likely to support AI adoption than White and Asian people. Poor knowledge of AI, fear of job loss, and resistance to change were the top barriers to AI adoption and embedding. CONCLUSIONS AI use in health is global, but the adoption rate varies by geography and individual characteristics. AI adoption communication by executive health care management is poor, as is the level of training of health care staff. To improve AI adoption, management should improve communication with their teams, provide training on AI to their workers, and help individuals understand how AI works. Barriers such as ethical issues around data ownership and use should be addressed. African organizations should be proactive and invest in AI adoption early, so that they are not left behind in the AI revolution.